MedTrace Logo

Liver Status and Presence of MASLD/MASH in Patients With Chronic Hepatitis B

NCT06573190 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2024-08-27

No results posted yet for this study

Summary

The aim of the study was to evaluate the consistency between liver biopsy and Liver Stiffness Measurement (LSM) for fibrosis and controlled attenuation parameter (CAP) for steatosis in FibroScan® in patients with chronic hepatitis B. The secondary aim of the study was to demonstrate the efficacy of FibroScan® for following the CHB patients at 12th month of antiviral therapy.

The study was prospectively planned in four different centers. Patients with HBsAg positivity for more than six months and HBV-DNA\>2,000 IU/mL, underwent liver biopsy and FibroScan® together within two week. FibroScan® was performed twice, before the antiviral therapy and one year later.

Conditions

Interventions

DIAGNOSTIC_TEST

Transient elastography

Liver Stiffness Measurement, Controlled Attenuation Parameter

DRUG

Tenofovir Disoproxil Fumarate

Guided Therapy

Sponsors & Collaborators

  • Nobel Pharmaceuticals

    collaborator INDUSTRY

  • Yaşar Bayındır, MD

    lead OTHER

Principal Investigators

  • Mustafa Kemal Çelen, MD · Dicle University, Medical Faculty, Department of Infectious Diseases

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-02
Primary Completion
2023-04-25
Completion
2024-05-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06573190 on ClinicalTrials.gov